Skip to content

Genetic test for pathogenic variants in the *GPD1* gene (using DNA extracted from blood)

Published: August 9, 2026Updated: August 16, 2026

This test checks for harmful changes (mutations) in the *GPD1* gene, which may be linked to certain metabolic or genetic conditions.

Quick summary

["A genetic test to identify potential gene mutations that could affect metabolism or health."]

Medically reviewed by WellAlly Editorial TeamLast reviewed August 16, 2026Editorial policy

Key facts at a glance

LOINC
104724-0
Short code
Gp B Strep DNA Spec Ql
Synonyms
Gp B Strep DNA Spec Ql
Category
coagulation
Sample
serum
Container
Red-top tube (SST)
Units
N/A
Fasting
false
Population
adult
Sex
all
Age range
18–65 years
Method
molgen
Specimen volume
5 mL
Stability
Room temperature: 4h, Refrigerated: 24h, Frozen: 7d
Hemolysis max
500
Lipemia max
1000
Icterus max
500
TAT
4–24 hours
Order
routine

What This Test Measures

The *GPD1* gene provides instructions for making an enzyme called glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Mutations in this gene can sometimes lead to rare metabolic disorders or may be associated with inherited conditions. This test detects specific harmful variants in the DNA sequence of this gene.

Why It Might Be Ordered

Your healthcare provider may recommend this test if you have symptoms of a metabolic disorder, a family history of genetic conditions, or if genetic testing is part of a broader evaluation for unexplained health concerns.

Sample and Testing Process

A small blood sample is collected to extract DNA. The DNA is then analyzed for known pathogenic variants in the *GPD1* gene using advanced laboratory techniques.

What to Expect Before the Test

No special preparation is needed. You may be asked to fast or avoid certain medications, but your provider will clarify this if applicable.

Clinical interpretation

How abnormal results are interpreted and what conditions they suggest.

Mutations in the *GPD1* gene are rare and may cause metabolic issues such as hypoglycemia (low blood sugar) or other metabolic disorders. Identifying these mutations can help guide treatment plans, especially in inherited conditions. This test is primarily used for diagnostic or research purposes in specific clinical scenarios.

Short name

GPD1 Gene Pathogenic Variant Test

Frequently asked questions

What does a positive result mean?
A positive result indicates the presence of a pathogenic variant in the *GPD1* gene that may increase the risk of a metabolic disorder. This finding should be discussed with your healthcare provider to determine next steps, such as further genetic counseling or specialized management.
Will this test be covered by insurance?
Coverage depends on your insurance plan, medical necessity, and whether this test is part of a broader diagnostic evaluation. Check with your insurance provider or healthcare team for details.
How long will it take to get results?
Results are typically available within 1–2 weeks after the sample is processed. Your healthcare provider will contact you directly with the results and any recommendations.
  1. 1
    MedlinePlus — Laboratory TestsSource
  2. 2
    Lab Tests OnlineSource
  3. 3
    Mayo Clinic — Tests & ProceduresSource

Click any link to access the full source. PubMed Central (PMC) links provide free full-text access.

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 16, 2026. · Read our editorial policy